Main page News Price List Research Education Events Staff Contacts
Genetic Counselling Services Clinical Services Laboratory Services Armenian Society of Human Genetics
Laboratory Services

Immunopathology Laboratory

Our laboratory faculty and staff appreciate the trust you place in us, and we strive everyday to provide exceptional service for our referring physicians, genetic counselors and most importantly, the families they serve.

We offer the following tests for oncology:
1. Estrogen and Progesterone receptors (method of immunohistochemistry)
2. Her-2/neu (method of immunohistochemistry, FISH)
3. Ki-67 (method of immunohistochemistry)
4. P53 receptor (method of immunohistochemistry)

Immunohistochemical Testing of Estrogen and Progesterone Receptors

Estrogen (ER) and progesterone (PR) receptors are nuclear hormone receptors found in certain cells throughout the body. ERs and PRs are expressed in about 70% and 60% of invasive breast cancers, respectively. These tumors are named hormone-dependent because estrogen and/or progesterone hormones affect their growth. Status of ERs and PRs must be checked as an essential part of an initial analysis of all primary breast cancers. ER and PR are weak factors for prognosis but are strong predictive factors for response to endocrine therapies.

Patients with ER/PR- positive tumors tend to have a better-than-average prognosis to respond to endocrine therapy than those with ER/PR- negative tumors. 

HER2/neu (also known as ErbB-2) stands for "Human epidermal growth factor receptor 2" and it is a protein giving higher aggressiveness in breast cancers. It is encoded by the ERBB2 gene. Approximately 15-20% of breast cancers have an amplification of the HER2/neu gene or overexpression of its protein product. Overexpression of HER2/neu in breast cancer is associated with increased disease recurrence and worse prognosis. Because of its prognostic role as well as its ability to predict response to Trastuzumab (Herceptin), breast tumors are routinely checked for overexpression of HER2/neu. HER2/neu is also used as a predictor of response to therapy such as resistance to hormonal therapy. Therefore, HER2/neu testing is not diagnostic but helps physicians to understand more about tumor’s characteristics and to choose the treatment options.

Overexpression also occurs in other cancer such as ovarian cancer, stomach cancer, esophageal cancer, and biologically aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.

Since January, 2011 CMG was starting additional tests for Her-2/neu

FISH: Fluorescence In Situ Hybridization - uses fluorescent probes to look at the number of HER2 gene copies in the tumor cell. If there are more than 2 copies of the HER2 gene, then the cancer is HER2 positive.

Ki-67: Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The Ki-67 is a marker of proliferation. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy. 

P53 plays an important role in cell cycle control and apoptosis. Defective p53 could allow abnormal cells to proliferative, resulting in cancer. High p53 is a sign of poor prognosis associated with a bad chance of clinical response to chemotherapy. 

For Estrogen/Progesterone/Hercep, Ki-67, p53 immunohistoche-mical tests and FISH/CISH, please contact:
Laboratory of Biochemistry and Immunopathology 
Tel: (+ 374) 10 544367
Fax: (+ 374) 10 544366

Estrogen Receptor (ER) 25 000 AMD
Progesteron Receptor (PR) 25 000 AMD
Her-2-neu oncoprotein (Epidermal Growth Factor Receptor (EGFR ) Type 2) 15 000 AMD
Ki-67 (Marker of proliferation) 10 000 AMD
P53 (Marker of apoptosis) 15 000 AMD
Detection of Her2-neu oncoprotein by FISH 75 000 AMD
Estrogen, Progesteron Receptors and Her2-neu: Complex investigation 65 000 AMD
Estrogen, Progesteron Receptors and Her2-neu, Ki67: Complex investigation 75 000 AMD
Estrogen, Progesteron Receptors and Her2-neu, Ki67, p53: Complex investigation 85 000 AMD
C3c, complement 3 000 AMD
C4, complement 3 000 AMD
Immunoglobulin A 3 000 AMD
Immunoglobulin M 3 000 AMD
Immunoglobulin G 3 000 AMD

Armine Arakelyan
Alla Manukyan

Copyright © 2015-2018 Center of Medical Genetics and Primary Health Care. All rights reserved.